Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:acquisitionYear |
2018
|
| gptkbp:CEO |
Peter Van Vlasselaer
|
| gptkbp:focus |
immuno-oncology
|
| gptkbp:foundedYear |
2012
|
| gptkbp:fullName |
ARMO BioSciences, Inc.
|
| gptkbp:headquartersLocation |
gptkb:Redwood_City,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
ARMO
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
pegilodecakin
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ARMO
|
| gptkbp:bfsParent |
gptkb:Indian_Army_Reserve_of_Medical_Officers
|
| gptkbp:bfsLayer |
7
|